AVLN
insider transactionsAvalyn Pharma Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 3 different insiders made open-market purchases in the last 90 days, totalling $25.0M.
Net shares · 90d
+1.4M
1.4M buy · 0 sell
Net value · 90d
$25.0M
$25.0M in · $0 out
Sentiment · 90d
Net buying
100% buying · 0% selling
Open-market trades · 90d
4
1.4M buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·C
Director
—
9.4M sh
Own New
-
Exercise·C
Director
—
27.3M sh
Own New
-
Buy·P
Director
$5.0M
277.8K sh · $18.00
Own +15%
-
Exercise·C
Director
—
489.5K sh
Own +34%
-
Exercise·C
Director
—
1.4M sh
Own New
-
Exercise·C
—
9.4M sh
Own New
-
Exercise·C
—
6.8M sh
Own New
-
Exercise·C
—
9.4M sh
Own New
-
Exercise·C
—
27.3M sh
Own New
-
Buy·P
$5.0M
277.8K sh · $18.00
Own +33%
-
Exercise·C
—
354.8K sh
Own New
-
Buy·P
$5.0M
277.8K sh · $18.00
Own +15%
-
Exercise·C
—
489.5K sh
Own +34%
-
Exercise·C
—
1.4M sh
Own New
-
Exercise·C
$0
4.1M sh
Own New
-
Exercise·C
$0
20.5M sh
Own New
-
Exercise·C
—
1.3M sh
Own New
-
Exercise·C
10% Owner
$0
12.6M sh
Own New
-
Exercise·C
10% Owner
$0
5.6M sh
Own New
-
Exercise·C
10% Owner
$0
25.9M sh
Own New
-
Exercise·C
10% Owner
$0
2.0M sh
Own New
-
Exercise·C
10% Owner
$0
18.0M sh
Own New
-
Buy·P
10% Owner
$10.0M
555.6K sh · $18.00
Own +17%
-
Exercise·C
10% Owner
—
3.3M sh
Own New
-
Exercise·C
Other, 10% Owner
—
377.9K sh
Own New
-
Exercise·C
Other, 10% Owner
—
225.8K sh
Own New
-
Exercise·C
Other, 10% Owner
—
872.9K sh
Own New
-
Exercise·C
Other, 10% Owner
—
80.3K sh
Own New
-
Exercise·C
Other, 10% Owner
—
727.6K sh
Own New
-
Exercise·C
Other, 10% Owner
—
377.9K sh
Own +20%
-
Exercise·C
Other, 10% Owner
—
225.8K sh
Own +13%
-
Exercise·C
Other, 10% Owner
—
872.9K sh
Own +108%
-
Exercise·C
Other, 10% Owner
—
80.3K sh
Own +11%
-
Exercise·C
Other, 10% Owner
—
727.6K sh
Own New
-
Grant·A
Chief Financial Officer
$0
212.0K sh
Own New
-
Grant·A
Director
$0
27.0K sh
Own New
-
Grant·A
Director
$0
27.0K sh
Own New
-
Grant·A
Director
$0
27.0K sh
Own New
-
Grant·A
Chief Operating Officer
$0
212.0K sh
Own New
-
Grant·A
Director
$0
27.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
212.0K sh
Own New
-
Grant·A
Lyn Baranowski KEY
Chief Executive Officer
$0
501.0K sh
Own New
-
Grant·A
General Counsel
$0
254.9K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 1, 2026 | Jill Carroll | Exercise C | 9.4M | — |
| May 1, 2026 | Jill Carroll | Exercise C | 27.3M | — |
| May 1, 2026 | Jill Carroll | Buy P | 277.8K | $5.0M |
| May 1, 2026 | Jill Carroll | Exercise C | 489.5K | — |
| May 1, 2026 | Jill Carroll | Exercise C | 1.4M | — |
| May 1, 2026 | SR ONE CAPITAL MANAGEMENT, LLC / Simeon George | Exercise C | 9.4M | — |
| May 1, 2026 | SR ONE CAPITAL MANAGEMENT, LLC / Simeon George | Exercise C | 6.8M | — |
| May 1, 2026 | SR ONE CAPITAL MANAGEMENT, LLC / Simeon George | Exercise C | 9.4M | — |
| May 1, 2026 | SR ONE CAPITAL MANAGEMENT, LLC / Simeon George | Exercise C | 27.3M | — |
| May 1, 2026 | SR ONE CAPITAL MANAGEMENT, LLC / Simeon George | Buy P | 277.8K | $5.0M |
| May 1, 2026 | SR ONE CAPITAL MANAGEMENT, LLC / Simeon George | Exercise C | 354.8K | — |
| May 1, 2026 | SR ONE CAPITAL MANAGEMENT, LLC / Simeon George | Buy P | 277.8K | $5.0M |
| May 1, 2026 | SR ONE CAPITAL MANAGEMENT, LLC / Simeon George | Exercise C | 489.5K | — |
| May 1, 2026 | SR ONE CAPITAL MANAGEMENT, LLC / Simeon George | Exercise C | 1.4M | — |
| May 1, 2026 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | Exercise C | 4.1M | $0 |
| May 1, 2026 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | Exercise C | 20.5M | $0 |
| May 1, 2026 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | Exercise C | 1.3M | — |
| May 1, 2026 | Novo Holdings A/S | Exercise C | 12.6M | $0 |
| May 1, 2026 | Novo Holdings A/S | Exercise C | 5.6M | $0 |
| May 1, 2026 | Novo Holdings A/S | Exercise C | 25.9M | $0 |
| May 1, 2026 | Novo Holdings A/S | Exercise C | 2.0M | $0 |
| May 1, 2026 | Novo Holdings A/S | Exercise C | 18.0M | $0 |
| May 1, 2026 | Novo Holdings A/S | Buy P | 555.6K | $10.0M |
| May 1, 2026 | Novo Holdings A/S | Exercise C | 3.3M | — |
| May 1, 2026 | FMR LLC | Exercise C | 377.9K | — |
| May 1, 2026 | FMR LLC | Exercise C | 225.8K | — |
| May 1, 2026 | FMR LLC | Exercise C | 872.9K | — |
| May 1, 2026 | FMR LLC | Exercise C | 80.3K | — |
| May 1, 2026 | FMR LLC | Exercise C | 727.6K | — |
| May 1, 2026 | FMR LLC | Exercise C | 377.9K | — |
| May 1, 2026 | FMR LLC | Exercise C | 225.8K | — |
| May 1, 2026 | FMR LLC | Exercise C | 872.9K | — |
| May 1, 2026 | FMR LLC | Exercise C | 80.3K | — |
| May 1, 2026 | FMR LLC | Exercise C | 727.6K | — |
| Apr 30, 2026 | Douglas R Carlson KEY | Grant A | 212.0K | $0 |
| Apr 30, 2026 | Erin Lavelle | Grant A | 27.0K | $0 |
| Apr 29, 2026 | Jon Congleton | Grant A | 27.0K | $0 |
| Apr 29, 2026 | Heather D Turner | Grant A | 27.0K | $0 |
| Apr 29, 2026 | Melissa Rhodes | Grant A | 212.0K | $0 |
| Apr 29, 2026 | Kate Haviland | Grant A | 27.0K | $0 |
| Apr 29, 2026 | Howard Lazarus | Grant A | 212.0K | $0 |
| Apr 29, 2026 | Lyn Baranowski KEY | Grant A | 501.0K | $0 |
| Apr 29, 2026 | Adam H. Golden | Grant A | 254.9K | $0 |
About AVLN insider trading
This page tracks insider transactions for Avalyn Pharma Inc. (AVLN) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.